Wyeth

Medimmune Limited

Yulia Vugmeyster

Davinder Gill

Deborah A Young

Laird Bloom

David C Lowe

Viia Valge-Archer

Margot O'Toole

Maya Arai

Amy Arlene Weaver

Sadhana Jain

Heath M Guay

Karissa K Adkins

The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.

Methods of treatment utilizing binding proteins of the interleukin-21 receptor

The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Interleukin-21 receptor binding proteins

Growing community of inventors

North Reading, MA, United States of America

Yulia Vugmeyster